Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (ChiCTR2600132648) titled 'Prognostic performance of ALBI and PALBI scores in patients with hepatocellular carcinoma undergoing transarterial chemoembolization' on Sept. 16.
Study Type: Observational study
Study Design:
Cohort study
Primary Sponsor: Shenzhen Second People's Hospital
Condition:
Primary liver cancer
Recruitment Status: Recruiting
Phase: N/A
Date of First Enrollment: 2026-06-30
Target Sample Size: Observation group:100;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=328846
Published by HT Digital Content Services with permission from Health Daily Digest....